Efficacy of Diabetinol™ on glycemic control in insulin resistant hamsters and subjects with impaired fasting glucose – a pilot study

The anti-diabetic potential of Diabetinol™ was tested in an animal model and in a pilot study in humans. Male Syrian golden hamsters (n = 18) were fed regular chow, 60% fructose or a 60% fructose diet + 1% Diabetinol™. Hamsters fed 60% fructose + 1% Diabetinol™ demonstrated a decrease in blood glucose, serum insulin, total cholesterol and triacylglycerol levels as compared to the fructose-fed animals. Efficacy of Diabetinol™ (2 × 525 mg/day) was investigated in a randomized, placebo-controlled, double-blind trial where subjects (n = 19) with impaired fasting glucose (IFG) on either Diabetinol™ or placebo were presented with a standard oral glucose challenge. After 84 days of supplementation a significant reduction (p < 0.01) in glucose intolerance, total cholesterol, LDL-cholesterol and decreasing trends in the HbA1c were observed in subjects supplemented with Diabetinol™. This study demonstrated an important future role for the Diabetinol™ in glycemic control and management of risk factors in subjects with IFG on oral medication.